Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson has reiterated a Buy rating for Exact Sciences (NASDAQ:EXAS) and maintained a price target of $75.
September 13, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Mikson has reiterated a Buy rating for Exact Sciences and maintained a price target of $75, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100